G6PD A-variant influences the antibody responses to Plasmodium falciparum MSP2

Infection, Genetics and Evolution

Volumn 11, Issue 6, 2011, Pages 1287-1292

  Courtin, David ^a,b,c,d   Milet, Jacqueline ^a,b,c,d   Bertin, Gwladys ^a,b   Vafa, Manijeh ^e   Sarr, Jean Birame ^f   Watier, Laurence ^g   Deloron, Philippe ^a,b   Troye Blomberg, Marita ^e   Garcia, André ^a,b   Migot Nabias, Florence ^a,b  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Faculté des Sciences de la Santé et   (Benin)

^d UNIVERSITY OF ABOMEY CALAVI   (Benin)

^e STOCKHOLM UNIVERSITY   (Sweden)

^f INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^g INSERM   (France)

Author keywords

Antibody; G6PD; HbAS; Malaria; MSP2; Plasmodium falciparum; Sickle cell trait

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MEROZOITE SURFACE PROTEIN 2; RECOMBINANT PROTEIN;

ALPHA THALASSEMIA; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC TRAIT; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; NONHUMAN; PARASITE EXAMINATION; PARASITE PREVALENCE; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

ALPHA-THALASSEMIA; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MALARIA, FALCIPARUM; MALE; MULTIVARIATE ANALYSIS; PLASMODIUM FALCIPARUM; PREVALENCE; PROTOZOAN PROTEINS;

PLASMODIUM FALCIPARUM;

EID: 79960414906     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2011.04.016     Document Type: Article

References (32)

1. Aidoo M., Terlouw D.J., Kolczak M.S., McElroy P.D., ter Kuile F.O., Kariuki S., Nahlen B.L., Lal A.A., Udhayakumar V. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002, 359:1311-1312.
2. al-Yaman F., Genton B., Anders R., Taraika J., Ginny M., Mellor S., Alpers M.P. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunol. 1995, 17:493-501.
3. Aribot G., Rogier C., Sarthou J.L., Trape J.F., Balde A.T., Druilhe P., Roussilhon C. Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am. J. Trop. Med. Hyg. 1996, 54:449-457.
4. Aucan C., Traore Y., Tall F., Nacro B., Traore-Leroux T., Fumoux F., Rihet P. High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect. Immun. 2000, 68:1252-1258.
5. Ayi K., Turrini F., Piga A., Arese P. Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood 2004, 104:3364-3371.
6. Bayoumi R.A. Does the mechanism of protection from falciparum malaria by red cell genetic disorders involve a switch to a balanced TH1/TH2 cytokine production mode?. Med. Hypotheses 1997, 48:11-17.
7. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 1990, 172:1633-1641.
8. Cappadoro M., Giribaldi G., O'Brien E., Turrini F., Mannu F., Ulliers D., Simula G., Luzzatto L., Arese P. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 1998, 92:2527-2534.
9. Courtin D., Oesterholt M., Huismans H., Kusi K., Milet J., Badaut C., Gaye O., Roeffen W., Remarque E.J., Sauerwein R., Garcia A., Luty A.J. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PloS One 2009, 4:e7590.
10. Enevold A., Lusingu J.P., Mmbando B., Alifrangis M., Lemnge M.M., Bygbjerg I.C., Theander T.G., Vestergaard L.S. Reduced risk of uncomplicated malaria episodes in children with alpha+-thalassemia in northeastern Tanzania. Am. J. Trop. Med. Hyg. 2008, 78:714-720.
11. Ferreira M.U., Hartl D.L. Plasmodium falciparum: worldwide sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-2 (MSP-2). Exp. Parasitol. 2007, 115:32-40.
12. Friedman M.J. Erythrocytic mechanism of sickle cell resistance to malaria. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:1994-1997.
13. Graves P., Gelband H. Vaccines for preventing malaria (blood-stage). Cochrane Database Syst. Rev. 2006, CD006199.
14. Guindo A., Fairhurst R.M., Doumbo O.K., Wellems T.E., Diallo D.A. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med. 2007, 4:e66.
15. Kinyanjui S.M., Conway D.J., Lanar D.E., Marsh K. IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar. J. 2007, 6:82.
16. Koram K.A., Owusu-Agyei S., Utz G., Binka F.N., Baird J.K., Hoffman S.L., Nkrumah F.K. Severe anemia in young children after high and low malaria transmission seasons in the Kassena-Nankana district of northern Ghana. Am. J. Trop. Med. Hyg. 2000, 62:670-674.
17. Kwiatkowski D.P. How malaria has affected the human genome and what human genetics can teach us about malaria. Am. J. Hum. Genet. 2005, 77:171-192.
18. Lyon J.A., Thomas A.W., Hall T., Chulay J.D. Specificities of antibodies that inhibit merozoite dispersal from malaria-infected erythrocytes. Mol. Biochem. Parasitol. 1989, 36:77-85.
19. Metzger W.G., Okenu D.M., Cavanagh D.R., Robinson J.V., Bojang K.A., Weiss H.A., McBride J.S., Greenwood B.M., Conway D.J. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol. 2003, 25:307-312.
20. Migot-Nabias F., Pelleau S., Watier L., Guitard J., Toly C., De Araujo C., Ngom M.I., Chevillard C., Gaye O., Garcia A. Red blood cell polymorphisms in relation to Plasmodium falciparum asymptomatic parasite densities and morbidity in Senegal. Microbes Infect. 2006, 8:2352-2358.
21. Polley S.D., Conway D.J., Cavanagh D.R., McBride J.S., Lowe B.S., Williams T.N., Mwangi T.W., Marsh K. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 2006, 24:4233-4246.
22. Robert V., Dieng H., Lochouran L., Traore S.F., Trape J.F., Simondon F., Fontenille D. Malaria transmission in the rural zone of Niakhar, Senegal. Trop. Med. Int. Health 1998, 3:667-677.
23. Ruwende C., Khoo S.C., Snow R.W., Yates S.N., Kwiatkowski D., Gupta S., Warn P., Allsopp C.E., Gilbert S.C., Peschu N., et al. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 1995, 376:246-249.
24. Sarr J.B., Pelleau S., Toly C., Guitard J., Konate L., Deloron P., Garcia A., Migot-Nabias F. Impact of red blood cell polymorphisms on the antibody response to Plasmodium falciparum in Senegal. Microbes Infect. 2006, 8:1260-1268.
25. Snewin V.A., Herrera M., Sanchez G., Scherf A., Langsley G., Herrera S. Polymorphism of the alleles of the merozoite surface antigens MSA1 and MSA2 in Plasmodium falciparum wild isolates from Colombia. Mol. Biochem. Parasitol. 1991, 49:265-275.
26. Taylor R.R., Allen S.J., Greenwood B.M., Riley E.M. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am. J. Trop. Med. Hyg. 1998, 58:406-413.
27. Theander T.G. Unstable malaria in Sudan: the influence of the dry season. Malaria in areas of unstable and seasonal transmission. Lessons from Daraweesh. Trans. R. Soc. Trop. Med. Hyg. 1998, 92:589-592.
28. Tongren J.E., Drakeley C.J., McDonald S.L., Reyburn H.G., Manjurano A., Nkya W.M., Lemnge M.M., Gowda C.D., Todd J.E., Corran P.H., Riley E.M. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect. Immun. 2006, 74:257-264.
29. Vickers A.J., Altman D.G. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001, 323:1123-1124.
30. Wambua S., Mwangi T.W., Kortok M., Uyoga S.M., Macharia A.W., Mwacharo J.K., Weatherall D.J., Snow R.W., Marsh K., Williams T.N. The effect of alpha+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med. 2006, 3:e158.
31. Williams T.N. Red blood cell defects and malaria. Mol. Biochem. Parasitol. 2006, 149:121-127.
32. Williams T.N., Wambua S., Uyoga S., Macharia A., Mwacharo J.K., Newton C.R., Maitland K. Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood 2005, 106:368-371.